CTOs on the Move

Marathon Kids

www.marathonkids.org

 
Marathon Kids is a nonprofit organization, headquartered in Austin, TX, that is dedicated to improving the health of children by providing them with the motivation, tools and support to live happier, healthier lifestyles. Marathon Kids started out with the simple mission to introduce children to the joy of running, but it has evolved into the only evidence-based running/walking program for elementary-school kids in the United States. We`ve stood up to rigorous tests to prove that our program mitigates the negative health effects of a sedentary lifestyle and ardently pushes for access around the country. The vast majority of kids don`t ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.marathonkids.org
  • 4544 South Lamar Blvd. Bldg 300 Suite 350
    Austin, TX USA 78745
  • Phone: 512.477.1259

Executives

Name Title Contact Details
Anne-Marie Tucker
Chief Technology Officer Profile

Similar Companies

Medical Information Technology, Inc.

Medical Information Technology, Inc. (MEDITECH) is engaged in developing, manufacturing and marketing of computer software products for the hospital industry. The wholly owned subsidiary of the Company is Patient Care Technologies, Inc. (PtCT).

St. Luke's Hospital and Health Network

St. Luke's Hospital and Health Network is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Bethlehem, PA. To find more information about St. Luke's Hospital and Health Network, please visit www.slhn.org

Bio Research Associates

Bio Research Associates is a Milwaukee, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ferring Pharmaceuticals

Ferring Pharmaceuticals is a private multinational biopharmaceutical company specialising in areas such as reproductive health, maternal health, gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years.

RaNA Therapeutics

RaNA Therapeutics is pioneering the discovery of a new class of RNA-targeted medicines that selectively activate protein expression within the body`s own cells. By targeting specific genes, RaNA`s novel drugs work epigenetically to precisely upregulate the expression of beneficial proteins in order to treat or prevent disease. The company`s leadership leverages preeminent founders and advisors in the field, and the strength of its fundamental patents, technology, and know-how that underlie the discovery and development of therapeutics that selectively activate RNA. RaNA is applying its proprietary technology to rapidly advance a pipeline of novel drugs for diverse therapeutic areas, with an initial emphasis in the fields of rare genetic disorders, inflammation, oncology, metabolic diseases and neurodegenerative diseases.